

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Peter R. Rhode, et al.

EXAMINER:

Not yet assigned

SERIAL NO.: 09/766,378

GROUP ART UNIT NO.: 1646

FILED:

January 19, 2001

FOR:

SOLUBLE MHC COMPLEXES AND METHODS OF USE THEREOF

HON. COMMISSIONER OF PATENTS AND TRADEMARKS WASHINGTON, DC 20231

Sir:

CERTIFICATE OF MAILING

I hereby certify that this SUBMISSION OF "SEQUENCE LISTING," COMPUTER READABLE COPY, AND/OR AMENDMENT PERTAINING THERETO FOR BIOTECHNOLOGY INVENTION CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE (Transmittal), COPY OF COMMUNICATION DATED April 3, 2001, STATEMENTS IN SUPPORT OF FILING AND SUBMISSIONS IN ACCORDANCE WITH 37 CFR §§1.821-1.825, SEQUENCE LISTING COMPUTER PRINTOUT, 31/2" FLOPPY DISK CONTAINING THE SEQUENCE LISTING, and SUBSTITUTE PAGES (Sheets 114-128) for the above-identified Application are being deposited with the United States Postal Service as first class mail in an envelope addressed to Honorable. Commissioner of Patents and Trademarks, Washington, DC 20231, on this 17th day of May, 2001.



Docket No. 48002-DIV (71758)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Peter R. Rhode, et al.

Serial No.: 09/766,378

Group Art Unit No.: 1646

Filed: January 19, 2001

Examiner: Not yet assigned

For: SOLUBLE MHC COMPLEXES AND METHODS OF USE THEREOF

Hon. Commissioner of Patents and Trademarks

Washington, DC 20231

CERTIFICATE OF MAILING UNDER 37 CFR 1.10

I, Patricia A. Barnes, hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC 20231 on May 17, 2001.

Patricia A Barnes

Sir:

PRELIMINARY AMENDMENT

In response to the Notice to Comply mailed April 3, 2001 (copy enclosed), please amend the above-identified application as follows:

IN THE SPECIFICATION:

Please substitute the originally-filed pages 114-127 with the substitute sheets 114-128 attached hereto and renumber the claim pages and abstract accordingly.

REMARKS

Consideration of this Preliminary Amendment is requested prior to examination of the above-captioned application. The present submission introduces no new matter.